FDA Approves GSK’s Prostate Drug Jalyn

GlaxoSmithKline June 14 announced that the Food and Drug Administration has approved Jalyn, a single-capsule combination of dutasteride and tamsulosin, to treat symptomatic benign prostatic hyperplasia in men with an enlarged prostate.

Common symptoms of BPH caused by an enlarged prostate include awakening at night to urinate, frequent urination, urgency, incomplete bladder emptying, starting and stopping, and weak stream, GlaxoSmithKline said. If left untreated, in severe cases, BPH can get worse over time and require catheterization or hospitalization for the inability to urinate, or prostate-related surgery.

The company said it expects to make the product available during the second half ...